GenVec TNFerade Potential Pulmonary Embolism Risk Prompts Clinical Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA initiates hold after three pulmonary embolisms, including one leading to death, are seen in highest dose studied in Phase II esophageal cancer trial. GenVec will provide additional data to FDA "over the next several days."